Search

Your search keyword '"Roche Holding Ltd. -- Product information"' showing total 50 results
Start Over Descriptor "Roche Holding Ltd. -- Product information" Topic pharmaceutical industry -- product information
50 results on '"Roche Holding Ltd. -- Product information"'

1. Larger size Deflatine launched

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries
Abstract

Roche has added a 36-tablet pack size to its Rennie Deflatine range. The new pack retails at #4.79. Roche Consumer Health. Tel: 01707 [...]

Published
2000

2. Oseltamivir Phosphate Capsules (Tamiflu--Roche Pharmaceuticals)

Author

Elliott, William T. and Chan, James

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Health, Tamiflu (Medication) -- Marketing
Abstract

IN OCTOBER, THE FDA APPROVED OSELTAMVIR (TAMI-flu--Roche), the second neuraminidase inhibitor for the treatment of influenza. This comes three months after the FDA approved zanamivir (Relenza) (Intern Med Alert 1999;21:133). [...]

Published
1999

3. Solutions for DNA copy-number analysis

Author

Ott, Vanessa L.

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Biotechnology industry, Business
Abstract

Roche's NimbleGen comparative genomic hybridization arrays enable genome-wide detection of DNA copy-number changes. The system requires minimal investment and no pror microarray experience. Other product features and dimensions are also supplied.

Published
2009

4. High-performance melting curve analysis

Author

Hoffman, Michael, Hurlebaus, Jochen, and Weilke, Christian

Subjects
Roche Holding Ltd. -- Product information, Genetic variation -- Research, Gene mutations -- Research, Biotechnology laboratories -- Equipment and supplies, Polymerase chain reaction -- Equipment and supplies, Pharmaceutical industry -- Product information, Biotechnology industry, Business
Abstract

Roche has developed the LightCycler 480 System, a drug discovery and genetic variation analysis platform which offers high-perfomance analysis of melting curve. It is the only plate-based real-time polymerase chain reaction (PCR) system that can scan mutation through high-performance melting curve analysis. Its various features and uses are discussed.

Published
2007

5. Roche's Tamiflu drug may not be approved in Europe by winter

Subjects
Europe -- Science and technology policy, Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Business, Business, general, Tamiflu (Medication) -- Laws, regulations and rules
Published
2000

6. Roche defers Tamiflu approval

Subjects
Roche Holding Ltd. -- Product information, Gilead Sciences Inc. -- Product information, Pharmaceutical industry -- Product information, Influenza vaccines -- Evaluation, Business, Business, general, Tamiflu (Medication) -- Evaluation
Published
2000

7. Heart drug boosts survival of patients, study suggests

Subjects
SmithKline Beecham PLC -- Product information, Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Heart failure -- Drug therapy, Business, Business, general, Carvedilol (Medication) -- Testing
Published
2000

9. Roche's studies on lipodystrophy syndrome

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Protease inhibitors -- Research, HIV infection -- Drug therapy, Business, Pharmaceuticals and cosmetics industries
Abstract

Roche's HIV protese inhibitor saquinavir has been linked to increases in triglyceride and cholesterol concentration in patients undergoing long-term treatment. The lipodystrophy syndrome is seen mostly in patients using saquinavor in combination with Abbott Laboratories' ritonavir.

Published
1999

10. PEG-interferon more effective

Subjects
Roche Holding Ltd. -- Product information, Hepatitis C -- Drug therapy, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Pegasys (Medication) -- Evaluation
Published
1998

11. CellCept endorsed for heart transplants

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Immunosuppressive agents -- Usage, Heart -- Transplantation, Business, Pharmaceuticals and cosmetics industries, CellCept (Medication) -- Usage
Published
1998

12. CSM on Fosamax & Lariam

Subjects
United Kingdom. Committee on Safety of Medicines -- Reports, Merck & Company Inc. -- Product information, Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Gastrointestinal agents -- Adverse and side effects, Mefloquine -- Adverse and side effects, Antimalarials -- Adverse and side effects, Alendronate -- Adverse and side effects, Business, Pharmaceuticals and cosmetics industries, Fosamax (Medication) -- Adverse and side effects, Lariam (Medication) -- Adverse and side effects
Published
1996

13. Protease inhibitors in France

Subjects
Roche Holding Ltd. -- Product information, HIV infection -- Drug therapy, Pharmaceutical industry -- Product information, Protease inhibitors -- Health aspects, Business, Pharmaceuticals and cosmetics industries
Published
1995

14. Protease inhibitor combinations for HIV?

Subjects
Abbott and Co. -- Product information, Roche Holding Ltd. -- Product information, HIV infection -- Drug therapy, Pharmaceutical industry -- Product information, Protease inhibitors -- Research, Business, Pharmaceuticals and cosmetics industries
Published
1995

15. Advances with protease inhibitors

Subjects
Boehringer Ingelheim GmbH -- Product information, Agouron Pharmaceuticals Inc. -- Product information, Vertex Pharmaceuticals Inc. -- Product information, Glaxo Wellcome PLC -- Product information, Roche Holding Ltd. -- Product information, Merck & Company Inc. -- Product information, Pharmaceutical industry -- Product information, Protease inhibitors -- Research, HIV infection -- Drug therapy, Business, Pharmaceuticals and cosmetics industries
Published
1995

16. First approvals for Roche's Vesanoid

Subjects
Roche Holding Ltd. -- Product information, Acute leukemia, Promyelocytic, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Vesanoid (Medication) -- Product introduction
Published
1995

17. Vesanoid data encouraging in APL

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Tretinoin -- Research, Acute leukemia, Promyelocytic -- Drug therapy, Antineoplastic agents -- Evaluation, Business, Pharmaceuticals and cosmetics industries, Vesanoid (Medication) -- Research
Published
1994

18. Zinecard/Vesanoid OK'd by FDA cm'tee

Subjects
Pharmacia Inc. -- Product information, Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Breast cancer -- Drug therapy, Acute leukemia, Promyelocytic -- Drug therapy, Antineoplastic agents -- Product development, Business, Pharmaceuticals and cosmetics industries
Published
1994

19. Hivid now available under French social security

Subjects
Roche Holding Ltd. -- Product information, AIDS (Disease) -- Drug therapy, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Hivid (Medication) -- Laws, regulations and rules
Published
1994

20. Roche's Pulmozyme approved in Spain

Subjects
Roche Holding Ltd. -- Product information, Cystic fibrosis -- Drug therapy, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Pulmozyme (Medication) -- Marketing
Published
1994

21. Fatal allergic reactions in Italian Rocefin patients

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Antibiotics -- Adverse and side effects, Ceftriaxone -- Adverse and side effects, Business, Pharmaceuticals and cosmetics industries, Rocephin (Medication) -- Adverse and side effects
Published
1994

22. FDA cm'ttee OKs Roche's fleroxacin

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Roche Holding Ltd. -- Product information, Drug approval -- Laws, regulations and rules, Pharmaceutical industry -- Product information, Quinolones -- Health aspects, Bacterial infections -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Megalone (Medication) -- Health aspects
Published
1994

23. Acitretin recommended for US approval

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Psoriasis -- Drug therapy, Acitretin -- Research, Dermatologic agents -- Research, Drug-alcohol interactions -- Research, Business, Pharmaceuticals and cosmetics industries, Soriatane (Medication) -- Research
Published
1994

24. Potential of moclobemide in anxiety disorders?

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Moclobemide -- Research, Panic disorders -- Drug therapy, Business, Pharmaceuticals and cosmetics industries
Published
1994

25. Co-trimoxazole for PCP prophylaxis

Subjects
Roche Holding Ltd. -- Product information, Wellcome PLC -- Product information, Pharmaceutical industry -- Product information, Co-trimoxazole -- Health aspects, Pneumocystis carinii pneumonia -- Prevention, Business, Pharmaceuticals and cosmetics industries
Published
1994

26. Trends in Alzheimer market

Subjects
Warner-Lambert Co. -- Product information, Hoechst AG -- Product information, Sigma-Tau Pharmaceuticals Inc. -- Product information, Sandoz Ltd. -- Product information, Roche Holding Ltd. -- Product information, Glaxo Inc. -- Product information, Bayer AG -- Product information, Alzheimer's disease -- Drug therapy, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries
Published
1993

27. Hivid recommended for zidovudine failures in the US

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, AIDS (Disease) -- Drug therapy, Zidovudine -- Dosage and administration, Drug therapy, Combination -- Research, Business, Pharmaceuticals and cosmetics industries, Hivid (Medication) -- Dosage and administration
Published
1993

28. Roche's Mazicon now Romazicon in the US

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Benzodiazepines -- Antagonists, Business, Pharmaceuticals and cosmetics industries, Mazicon (Medication) -- Names, Romazicon (Medication) -- Names
Published
1993

29. Roche/BMS discuss Inhibace brand name in Israel

Subjects
Roche Holding Ltd. -- Product information, Bristol-Myers Squibb Co. -- Product information, Pharmaceutical industry -- Product information, ACE inhibitors -- Names, Business, Pharmaceuticals and cosmetics industries, Inhibace (Medication) -- Marketing
Published
1993

30. New indications for alpha-interferon in Belgium

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Acute leukemia, Promyelocytic -- Drug therapy, Lymphomas -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Roferon-A (Medication) -- Usage
Published
1993

31. Recent product approvals in Denmark

Subjects
SmithKline Beecham Corp. -- Product information, Farmitalia Carlo Erba S.p.A. -- Product information, Roche Holding Ltd. -- Product information, Kabi Pharmacia AB -- Product information, Astra AB -- Product information, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Proscar (Medication) -- Marketing, Havrix (Vaccine) -- Marketing, Farmorubicin (Medication) -- Marketing, Neotigason (Medication) -- Marketing, Nicorette (Chewing gum) -- Marketing, Roxiam (Medication) -- Marketing
Published
1993

32. Antivirals in hepatitis B & C

Subjects
Roche Bioscience -- Product information, Ipsen-Biotech -- Product information, Roche Holding Ltd. -- Product information, Hepatitis B -- Drug therapy, Hepatitis C -- Drug therapy, Ganciclovir -- Research, Pharmaceutical industry -- Product information, Biotechnology industry -- Product information, Antiviral agents -- Research, Business, Pharmaceuticals and cosmetics industries, Roferon (Medication) -- Research
Published
1993

33. Recent product approvals in Switzerland

Subjects
Roche Holding Ltd. -- Product information, Klinge Pharma GmbH -- Product information, Astra AB -- Product information, Cephalosporins -- Marketing, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Globocef (Medication) -- Marketing, Aerocef (Medication) -- Marketing, Roxiam (Medication) -- Marketing
Published
1993

34. Perindropil and cilazapril now first-line in UK

Subjects
Servier Laboratories Ltd. -- Product information, Roche Holding Ltd. -- Product information, ACE inhibitors -- Health aspects, Hypertension -- Drug therapy, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries
Published
1993

35. Roche's protease inhibitor in US trials

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Protease inhibitors -- Testing, AIDS (Disease) -- Drug therapy, Business, Pharmaceuticals and cosmetics industries
Published
1993

36. NIH trial with Roche's TAT antagonist

Subjects
United States. National Institutes of Health -- Laws, regulations and rules, Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Drugs -- Testing, Business, Pharmaceuticals and cosmetics industries
Published
1992

37. US FDA crackdown on pirated DDC

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Zalcitabine -- Laws, regulations and rules, Business, Pharmaceuticals and cosmetics industries
Published
1992

38. Belgian midazolam ADR reports

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Midazolam -- Reports, Business, Pharmaceuticals and cosmetics industries
Published
1992

39. US review of Hivid in April?

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Hivid (Medication) -- Testing
Published
1992

40. US safety concerns on 'bootleg' DDC

Subjects
United States. Food and Drug Administration -- Standards, Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Zalcitabine -- Testing, Business, Pharmaceuticals and cosmetics industries, Hivid (Medication) -- Testing
Published
1992

41. Roche's Roferon-A for hepatitis C in Japan

Subjects
Roche Holding Ltd. -- Product information, Hepatitis C -- Drug therapy, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Roferon-A (Medication) -- Laws, regulations and rules
Published
1991

42. Roche files US NDA for Hivid

Subjects
Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Hivid (Medication) -- Laws, regulations and rules
Published
1991

43. Breast cancer and the FDA

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Roche Holding Ltd. -- Product information, Roche Holding Ltd. -- Licensing, certification and accreditation, Pharmaceutical industry -- Licensing, certification and accreditation, Pharmaceutical industry -- Product information, Administrative agencies -- Laws, regulations and rules, Breast cancer -- Care and treatment, Breast cancer -- Drug therapy, Drugs -- Complications and side effects, Drugs -- Licensing, certification and accreditation, Women -- Health aspects, Women -- Drug therapy, Cancer patients -- Care and treatment, Cancer patients -- Drug therapy, Women -- Forecasts and trends, Drug approval, Government regulation, Market trend/market analysis, News, opinion and commentary, Avastin (Medication) -- Licensing, certification and accreditation, Avastin (Medication) -- Complications and side effects
Published
2010

44. Roche drug faces FDA curb

Author

Mundy, Alicia

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Roche Holding Ltd. -- Licensing, certification and accreditation, Roche Holding Ltd. -- Product information, Breast cancer -- Drug therapy, Pharmaceutical industry -- Licensing, certification and accreditation, Pharmaceutical industry -- Product information, Drugs -- Adverse and side effects, Drugs -- Analysis, Drug approval, Revocation, Government regulation, News, opinion and commentary, Avastin (Medication) -- Health aspects, Avastin (Medication) -- Complications and side effects, Avastin (Medication) -- Licensing, certification and accreditation
Published
2010

45. FDA questions Avastin's use in breast cancer

Author

Dooren, Jennifer Corbett

Subjects
United States. Food and Drug Administration -- Investigations, Roche Holding Ltd. -- Product information, Breast cancer -- Drug therapy, Cancer patients -- Drug therapy, Cancer patients -- Care and treatment, Drugs -- Usage, Drugs -- Complications and side effects, Drugs -- Investigations, Drugs -- Health aspects, Administrative agencies -- Investigations, Pharmaceutical industry -- Product information, Women -- Health aspects, Women -- Care and treatment, Drugs -- Adverse and side effects, Company legal issue, News, opinion and commentary, Avastin (Medication) -- Usage, Avastin (Medication) -- Health aspects, Avastin (Medication) -- Complications and side effects, Avastin (Medication) -- Investigations
Published
2010

46. Roche cuts Tamiflu price for developing countries

Author

Mengewein, Julia

Subjects
Roche Holding Ltd. -- Prices and rates, Roche Holding Ltd. -- Product information, Developing countries -- Economic aspects, Developing countries -- Health policy, Influenza vaccines -- Prices and rates, Pharmaceutical industry -- Prices and rates, Pharmaceutical industry -- Product information, Company pricing policy, Company marketing practices, Product marketing strategy, News, opinion and commentary, Tamiflu (Medication) -- Prices and rates, Tamiflu (Medication) -- Marketing
Published
2009

47. Herceptin slows some stomach cancer

Author

Gryta, Thomas

Subjects
Roche Holding Ltd. -- Product information, Breast cancer -- Drug therapy, Breast cancer -- Care and treatment, Drugs -- Testing, Drugs -- Usage, Pharmaceutical industry -- Product information, Stomach cancer -- Drug therapy, Stomach cancer -- Care and treatment, News, opinion and commentary, Herceptin (Medication) -- Testing, Herceptin (Medication) -- Usage, Herceptin (Medication) -- Evaluation
Published
2009

48. In the war against flu's mutants, a big ally is weakened

Author

Goldstein, Jacob

Subjects
GlaxoSmithKline PLC -- Product information, Roche Holding Ltd. -- Product information, Microbial mutation -- Forecasts and trends, Drug resistance -- Forecasts and trends, Influenza -- Control, Influenza -- Drug therapy, Influenza vaccines -- Research, Influenza vaccines -- Usage, Influenza vaccines -- Evaluation, Drugs -- Evaluation, Drugs -- Usage, Pharmaceutical industry -- Product information, Market trend/market analysis, News, opinion and commentary, Tamiflu (Medication) -- Evaluation, Tamiflu (Medication) -- Usage, Relenza (Medication) -- Evaluation, Relenza (Medication) -- Usage
Abstract

The flu drug Tamiflu, manufactured by Roche Holding Ltd., has been found to be ineffective against a current flu strain which has various mutations rendering it impervious to treatment. The only other drug treatment available is the inhaled drug Relenza, produced by GlaxoSmithKline PLC.

Published
2009

49. Roche's antiobesity drug clears hurdle; U.S. panel's marketing clearance boosts stock

Author

Moore, Stephen D.

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Roche Holding Ltd. -- Product information, Pharmaceutical industry -- Product information, Banking, finance and accounting industries, Business, Business, international, Xenical (Medication) -- Laws, regulations and rules
Abstract

Roche Holding Ltd (Basel, Switzerland) gained marketing clearance for its antiobesity drug Xenical on Apr 23, 1999, causing the company's stock to jump 4.3%. Xenical was launched in Europe in Sep 1998, but its US launch was delayed while a possible breast cancer link was investigated. Marketing is expected to begin in early May 1999. One analyst expect Xenical sales to total 2.3 billion francs by 2005. For its first few years of release, Xenical is expected to dominate the market for obesity treatments, along with BASF AG's Meridia.

Published
1999

50. Neupogen's potential in clinical practice

Subjects
Amgen Inc. -- Product information, Roche Holding Ltd. -- Product information, Neutropenia -- Prevention, Pharmaceutical industry -- Product information, Cancer -- Care and treatment, Business, international, Neupogen (Medication) -- Testing
Published
1991

Catalog

Books, media, physical & digital resources
See catalog results